Floatz logo

xnw28012

Pancreatic Carcinoma

Evopoint Biosciences Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

103 Active assets in the Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
OHSU Knight Cancer Institute
Phase 2/3BBB
FLUOROURACILUM
Northwestern University
Phase 2/3BBB
Eloxatin
OHSU Knight Cancer Institute
Phase 2/3BBB
Gdc-0449
OHSU Knight Cancer Institute
Phase 2BB
Capecitabine
Zhejiang University
Phase 2BB

View all 50 →

Same molecule, other indications

xnw28012 is also rated in:

cervical cancerDormant
CC
Indicative ·
47 / 100
View asset →
cancerDormant
CC
Indicative ·
40 / 100
View asset →
ovarian cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →